51
Background:
Broad genomic profiling (BGP) is recommended for all patients with metastatic non-squamous NSCLC to guide targeted therapy (TT) selection. As actionable alterations and matched therapies continue to expand, BGP may identify a broader group of patients eligible for TT and consequently improve pati...
Si-Da Huang, John Rothen, Jessica B. Long et al.· JCO Oncology Practice· 0 citations
BACKGROUND
Cancer survivors face an increased risk of second primary malignancies (SPMs). Understanding SPM incidence and risk factors is crucial for long-term survivorship care.
METHODS
This was a SEER-Medicare retrospective cohort study of breast, prostate, colon, or rectal cancer survivors diagnosed between 2003-2...
Tendai Kwaramba, Sarah J. Westvold, Jessica B. Long et al.· Journal of the National Canc...· 0 citations
37
Background:
Broad genomic profiling (BGP) is increasingly used in metastatic non-small cell lung cancer (mNSCLC), but its association with downstream treatment-related Medicare spending compared to focused gene testing (FGT) remains unclear.
Methods:
We conducted a retrospective cohort study using SEER-Med...
Akintunde O. Aremu, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
40
Background:
The use of biologic therapy for patients with mCRC is incompletely characterized. We evaluated receipt of biomarker matched guideline concordant treatment with VEGF inhibitors (VEGFi), EGFR antibodies (EGFRa), and immune checkpoint inhibitors (ICI), assessing treatment by sociodemographic, clinic...
T. Salah, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.